Clinical efficacy of preoperative application of hydrochloride tirofiban in patients with acute coronary syndrome by percutaneous coronary intervention
10.3760/cma.j.issn.1008-6706.2012.20.015
- VernacularTitle:经皮腔内冠状动脉介入术前应用替罗非班治疗急性冠脉综合征的疗效观察
- Author:
Weihong LI
- Publication Type:Journal Article
- Keywords:
Hydrochloride tirofiban;
Acute coronary syndrome;
Angioplasty,transluminal,percutaneous coronary
- From:
Chinese Journal of Primary Medicine and Pharmacy
2012;19(20):3068-3070
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo observe the clinical efficacy and application value of preoperative application of hydrochloride tirofiban in patients with acute coronary syndrome(ACS) by percutaneous coronary intervention (PCI).Methods60 ACS patients underwent PIC surgery were randomly divided into observation group and control group.All patients underwent preoperative and postoperative regular routine anti-angina and acute myocardial infarction treatment,the observation group was given the hydrochloride tirofiban in 1h before surgery of emergency PCI,the control group received conventional therapy.The bleeding and thrombocytopenia occurrence during hospitalization of the two groups were observed,before surgery and 1 month after surgery the cardiac function of the two groups were compared,1 month after surgery the occurrence of adverse cardiovascular events were recorded.ResultsThe bleeding incidence of observation group was 6.7％,the control group was 23.3％,the difference between two groups was significant ( x2 =15.594,P ＜ 0.01 ) ; The thrombocytopenia occurrence of observation group was 3.3％,the control group was 10.0％,the difference between two groups was significant( x2 =13.366,P ＜ 0.01 ).1 month after surgery the LVEF,CO and E/A of the two groups increased significantly,compared with the prior-treatment,the difference was significant (P ＜ 0.05 ),and the difference was significant between the two groups( P ＜ 0.05 ) ;The occurrence of adverse cardiovascular events of observation group was 33.3％,the control group was 66.7％,the difference between two groups was significant(x2 =8.924,P ＜ 0.01 ).Conclusion The hydrochloride tirofiban is a safe and effective anti-platelet drugs.Preoperative application of hydrochloride tirofiban in patients with ACS by PCI can reduce the occurrence of cardiovascular events.
